2025
Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.
Palencia P, Zhao X, Kandala K, Smani S, Sivanesan N, Cavallo J, Leapman M. Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17123.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate radiation therapyMetastatic prostate cancerOverall survivalRadiation therapyProstate cancerM1c diseaseTreatment modalitiesRT to ADTTreated with androgen deprivation therapyAssociated with improved overall survivalHormone-sensitive prostate cancerAssociated with poor overall survivalPrimary local therapyExternal beam radiotherapyGleason grade groupCompare overall survivalNational Cancer DatabaseProstate cancer metastasisLog-rank testDisease burdenKaplan-Meier curvesCox proportional hazards modelsLow disease burden
2024
EBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature
Sampsonas F, Komninos D, Sotiropoulou V, Katsaras M, Gkanetsou D, Papaioannou O, Tsiri P, Tzelepi V, Tzouvelekis A. EBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/188870.Peer-Reviewed Original ResearchProstate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States.
Garraway I, Carlsson S, Nyame Y, Vassey J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States. Journal Of Clinical Oncology 2024, 42: 264-264. DOI: 10.1200/jco.2024.42.4_suppl.264.Peer-Reviewed Original ResearchBaseline PSA testingProstate Cancer FoundationBlack menPSA screeningPSA testingProstate cancerComprehensive literature searchFields of primary careHealth care providersProstate-specific antigen (PSA)-based prostate cancer screeningInterdisciplinary panel of expertsLiterature searchReduce prostate cancer mortalityPreferred Reporting ItemsMeta-analyses guidelinesProstate cancer screeningProstate cancer deathProstate cancer metastasisProstate cancer surveillanceScreening of menRandomized Controlled TrialsProstate cancer mortalityHigh-risk populationPrimary careRate of overdiagnosis
2020
Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2019
Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature.
Munshi F, Shinder B, Sadimin E, Mayer T, Singer E. Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature. Cancer Studies And Therapeutics 2019, 4 PMID: 32148662, PMCID: PMC7059776.Peer-Reviewed Case Reports and Technical NotesRenal pelvisProstate cancerProximal ureterSymptoms of obstructive uropathyHigh index of suspicionFive-year survival rateMetastatic work-upMetastatic prostate cancerProstate cancer metastasisIndex of suspicionRight renal pelvisUreteral metastasisAsymptomatic massObstructive symptomsProstatic adenocarcinomaObstructive uropathyEventual metastasisLymph nodesCase reportClinical trial protocolsHigh indexVisceral diseaseWork-upSurvival rateProstate
2018
Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.
Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.Peer-Reviewed Original ResearchHigh-risk CaPCAP mortalityM1 diseaseHazard ratioTime-varying Cox proportional hazards modelsHigh-risk prostate cancerCox proportional hazards modelHigh-risk CaP.Post-diagnostic useProstate cancer mortalityUse of statinsPopulation-based studyEffect of statinsProstate cancer metastasisCause of deathProportional hazards modelMetformin useSEER databaseRandomized trialsCancer mortalityProstate cancerMedicare filesStatinsHazards modelMetformin
2015
Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer
Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. Journal Of Palliative Medicine 2015, 18: 933-939. PMID: 26241733, PMCID: PMC4638209, DOI: 10.1089/jpm.2015.0171.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancer metastasisRadiation therapyTreatment courseProstate cancerBony metastasesEnd Results-Medicare dataRadiation treatmentCancer metastasisCost-effective palliationPalliative radiation therapyPalliative radiation treatmentGeneral patient populationShort treatment courseHospital-based settingStudy inclusion criteriaTotal Medicare paymentsRadiation treatment courseRadiation therapy techniquesLack of evidencePalliative radiationPalliative settingPalliative treatmentClinical benefitPatient population
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time
2010
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis
Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 2485-2490. PMID: 20080667, PMCID: PMC2823864, DOI: 10.1073/pnas.0908133107.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsbeta CateninBlotting, WesternCadherinsCell LineCell Line, TumorCell MovementEpithelial CellsGene ExpressionHumansImmunohistochemistryMaleMesodermMiceMice, NudeNeoplasm MetastasisNeoplasms, ExperimentalProstatic Neoplasmsras GTPase-Activating ProteinsReverse Transcriptase Polymerase Chain ReactionRNA, Small InterferingTCF Transcription FactorsTransfectionTransplantation, HeterologousVimentinConceptsProstate cancerMesenchymal transitionDAB2IP expressionCarcinoma cellsMultiple lymph nodesMetastatic prostate cancerDistant organ metastasisAggressive prostate cancerMetastatic PCa cellsProstate cancer metastasisClinical prostate cancer specimensHuman normal prostatePotential therapeutic targetXenograft mouse modelProstate cancer specimensProstate carcinoma cellsLymph nodesOrgan metastasisPCa cellsRole of DAB2IPPrognostic biomarkerPCa metastasisKnockout miceTherapeutic targetHuman carcinoma cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply